US News

Sanofi bets on mRNA vaccines beyond COVID in $3.2 billion Translate Bio deal

Published by
Reuters

By Matthias Blamont PARIS (Reuters) -Sanofi has agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal, as it bets on next-generation mRNA vaccine technology beyond the COVID-19 pandemic, confirming a Reuters exclusive report. Sanofi said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion. The boards of both companies have approved the deal, and the chief executive of Translate Bio and the U.S. company’s largest shareholder have backed it, Sanofi and Translate Bio said in a joint statem…

Read More

Facebook Comments

Check Also

The Atlantic's Franklin Foer Allegedly Identified As “Reporter-2” In The Sussmann Indictment

The Atlantic’s Franklin Foer Allegedly Identified As “Reporter-2” ...

Archives